Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial

Newsylist Editorial Desk. (2026, September 5, 2026). Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-09-05/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3

@online{newsylist_47133,
  author = {Newsylist Editorial Desk},
  title = {{Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-09-05/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3},
  note = {Tracked across 2 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial](https://www.newsylist.com/trend/2026-09-05/novartis-lp-a-drug-fails-to-lower-cardiovascular-risk-in-closely-watched-ph-3)), this event was corroborated across 2 independent sources with a live velocity of 1.